TG Therapeutics Inc (TGTX)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 13,062 | -198,335 | -348,101 | -279,381 | -172,870 |
| Revenue | US$ in thousands | 221,047 | 2,785 | 6,689 | 152 | 152 |
| Pretax margin | 5.91% | -7,121.54% | -5,204.08% | -183,803.29% | -113,730.26% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $13,062K ÷ $221,047K
= 5.91%
TG Therapeutics Inc's pretax margin has shown significant fluctuations over the past five years. In 2023, the pretax margin improved to 5.91%, indicating that the company generated a profit before taxes on its sales. However, in the previous years, particularly in 2020 and 2019, the company reported negative pretax margins of -183,803.29% and -113,730.26% respectively, indicating substantial losses relative to its revenue. The negative pretax margins in these years suggest that the company's expenses exceeded its revenue, resulting in significant operating losses. It is essential for TG Therapeutics Inc to continue monitoring and managing its expenses effectively to maintain positive pretax margins and improve its overall financial performance.
Peer comparison
Dec 31, 2023